Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Leukemia 70Lymphoma 52Leukemia, Myeloid, Acute 41Burkitt Lymphoma 36Myelodysplastic Syndromes 32Lymphoma, Non-Hodgkin 27Hodgkin Disease 27Lymphoma, Mantle-Cell 24Leukemia, Lymphocytic, Chronic, B-Cell 23Recurrence 21Lymphoma, Large B-Cell, Diffuse 21Graft vs Host Disease 21Lymphoma, Follicular 19Congenital Abnormalities 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Multiple Myeloma 17Leukemia, Myeloid, Accelerated Phase 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Myeloproliferative Disorders 15Leukemia, Myelomonocytic, Chronic 15Blast Crisis 15Lymphoma, B-Cell, Marginal Zone 14Leukemia, Myeloid, Chronic-Phase 13Lymphoma, Large-Cell, Immunoblastic 12Hematologic Neoplasms 12Primary Myelofibrosis 11Lymphoma, Large-Cell, Anaplastic 11Breast Neoplasms 11Neoplasms, Plasma Cell 10

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × Methotrexate × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00290498 2020-06-02

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

M.D. Anderson Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡